Abpro Holdings, Inc.

Abpro Holdings, Inc. (ABP) is a clinical-stage biopharmaceutical company focused on the development of bispecific antibody therapeutics, with oncology as a primary indication area. The company entered public markets through a SPAC merger and operates within the healthcare and life sciences sector. Abpro filed a Form 10-Q with the Securities and Exchange Commission on August 23, 2024, under accession number 0001193125-24-206165, providing a quarterly update on its financial condition and development-stage operations. As a post-merger public entity, Abpro continues to advance its proprietary antibody engineering platform toward clinical milestones. For complete filing history, deal metrics, and SPAC data on ABP, sign up for full access at SpacDesk.